Use of butyl phthalide and derivatives thereof in preparation of medicines for treating Parkinson disease

A technology for Parkinson's disease and derivatives, which is applied to the application field of butylphthalide and its derivatives in the preparation of medicines for treating Parkinson's disease, and can solve the problem of not teaching butylphthalide and its derivatives Parkinson's disease medicines, etc. problem, to achieve the effect of exact curative effect, improvement of pathogenesis, prevention or delay of progress

Inactive Publication Date: 2011-07-20
SHIJIAZHUANG PHARMA GRP NBP PHARMA CO LTD
View PDF4 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But the prior art does not teach that butylphthalide and derivatives thereof can be used for the preparation of medicines for the treatment of Parkinson's disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of butyl phthalide and derivatives thereof in preparation of medicines for treating Parkinson disease
  • Use of butyl phthalide and derivatives thereof in preparation of medicines for treating Parkinson disease
  • Use of butyl phthalide and derivatives thereof in preparation of medicines for treating Parkinson disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0011] Example 1 Butylphthalide

[0012] Observation in the rotenone PD rat model: intraperitoneal injection of butylphthalide to PD rats, and observe the effects of butylphthalide on the behavior, midbrain oxidative stress level and substantia nigra DA neurons of PD rats.

[0013] 1. Experimental materials

[0014] 1. Drug: butylphthalide, provided by CSPC NBP Pharmaceutical Co., Ltd.

[0015] 2. Reagents: Rotenone and apomorphine (APO) are products of Sigma; dimethyl sulfoxide (DMSO), tyrosine hydroxylase (TH) monoclonal antibody, and SABC kit are products of Wuhan Boster; GSH reagents The kit, MDA kit and SOD kit are products of Nanjing Jiancheng Company.

[0016] 3. Instruments: stereotaxic instrument for rat brain, Shenzhen Ruiwode Company; micro sample injector (5μl), Shanghai Third Analytical Instrument Factory; 721 spectrophotometer, Shanghai Precision Scientific Instrument Co., Ltd.; optical microscope, NikonYS100.

[0017] 4. Experimental animals: 50 female SD rat...

Embodiment 2

[0042] Example 2 L-Butylphthalide

[0043] Observation in the rotenone PD rat model: intraperitoneal injection of L-butylphthalide to PD rats, and observe the effects of L-butylphthalide on the behavior, midbrain oxidative stress level and substantia nigra DA neurons of PD rats.

[0044] One, test material is the same as embodiment 1

[0045] Two, test method is the same as embodiment 1

[0046] 3. Experimental results

[0047] (1) Observation of rotation behavior

[0048] 1. There was no significant difference in rotation behavior between the control group and each treatment group before treatment (P>0.05).

[0049] 2. Compared with before treatment, the number of rotations in the control group increased after treatment, and the number of rotations in the 20mg group decreased, but there was no statistical significance (P>0.05). The number of rotations in the 40mg and 80mg groups decreased after treatment compared with before treatment, and there was a significant differen...

Embodiment 3

[0071] Example 3 Propylenephthalide

[0072] Observation in the rotenone PD rat model: intraperitoneal injection of propylphthalide to PD rats to observe the effects of propylphthalide on the behavior, midbrain oxidative stress level and substantia nigra DA neurons of PD rats.

[0073] One, test material is the same as embodiment 1

[0074] Two, test method is the same as embodiment 1

[0075] 3. Experimental results

[0076] (1) Observation of rotation behavior

[0077] 1. There was no significant difference in rotation behavior between the control group and each treatment group before treatment (P>0.05).

[0078] 2. Compared with before treatment, the number of rotations in the control group increased after treatment, and the number of rotations in the 20mg and 40mg groups decreased, but there was no statistical significance (P>0.05). The number of rotations in the 80mg group decreased after treatment compared with that before treatment, and there was a significant diffe...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to new use of 3-n-butylphthalide (abbreviated as butyl phthalide) and derivatives thereof, in particular to the use of the compounds in the preparation of the medicine for treating Parkinson disease. A mat model of hemiparkinsonian disease is built by using three-dimensional targeted injection of rotenone to perform a test, and the result of the test shows that the butyl phthalide and derivatives thereof can effectively improve symptoms aroused by Parkinson and have a nerve-protecting effect.

Description

technical field [0001] The present invention relates to the new application of 3-n-butylphthalide (abbreviated as butylphthalide) and its derivatives, and more specifically relates to the application of the compound in the preparation of medicaments for treating Parkinson's disease. Background technique [0002] Parkinson's disease (PD) is a common chronic progressive neurodegenerative disease, and its characteristic pathological change is the degeneration and loss of dopamine (Dopamine, DA) neurons in the substantia nigra compacta. Currently, the etiology of PD is unknown. Theories about the pathogenesis of PD mainly include oxidative stress, mitochondrial dysfunction, calcium overload, toxic effects of excitatory amino acids, and apoptosis. The prevalence rate of people over 60 years old exceeds 1%, and increases with age. [0003] Alternative therapy represented by levodopa is currently the gold standard for PD. Not only can it not stop the natural process of the disease...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/365A61P25/16
CPCA61K31/365
Inventor 王涛黄憗牛锋黄金莎曹菊林郭海波
Owner SHIJIAZHUANG PHARMA GRP NBP PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap